Latest News

FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)





KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–FDA Accepts For Review sNDA for RECARBRIO™ for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Source link





Related posts

Long-term use of inexpensive weight-loss drug may be safe and effective

Newsemia

STAT Plus: Up and down the ladder: The latest comings and goings

Newsemia

Researchers identify potential drug target for multiple cancer types

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy